AstraZeneca PLC (AZN) stock profile

Frequently asked questions

What does AstraZeneca PLC (AZN) do?

AstraZeneca PLC is a biopharmaceutical company focused on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology indications. Its portfolio also includes Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare diseases. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has collaboration agreements with Neurimmune AG to develop and commercialize NI006, with BenevolentAI for drug discovery in systemic lupus erythematosus, with Lunit for AI-powered digital pathology risk assessment tools for NSCLC, and with Absci Corporation for AI-driven drug discovery against an oncology target. AstraZeneca was formerly known as Zeneca Group PLC and changed its name in April 1999. The company was incorporated in 1992 and is headquartered in Cambridge, United Kingdom.

Where is AZN stock listed?

AstraZeneca PLC trades under the ticker AZN on NYSE.

How can I research AZN's financials and filings?

Vantafin provides AstraZeneca PLC's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the AZN profile.